Overview

* Stryker Q3 net sales rise 10.3% to $6.1 bln, beating analyst expectations

* Adjusted EPS for Q3 increases 11.1% to $3.19, exceeding analyst estimates

* Company raises full-year guidance, citing strong sales momentum and margin expansion

Outlook

* Stryker raises 2025 organic net sales growth guidance to 9.8%-10.2%

* Company expects 2025 adjusted EPS between $13.50 and $13.60

Result Drivers

* MEDSURG AND NEUROTECHNOLOGY GROWTH - Segment sales increased 14.4% driven by 7.6% unit volume growth and 0.8% higher prices

* ORTHOPAEDICS GROWTH - Adjusted for divestitures, Orthopaedics sales grew 12.5% driven by 11.7% unit volume growth

* STRONG EXECUTION - CEO Kevin A. Lobo credits high-level execution for strong sales and earnings growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 net Beat $6.1 bln $6.04

sales bln (26

Analysts

)

Q3 Beat $3.19 $3.13

Adjusted (26

EPS Analysts

)

Q3 EPS $2.22

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Stryker Corp ( SYK ) is $435.00, about 15% above its October 29 closing price of $369.59

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)